Inspire Medical Systems develops and commercializes minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. Its proprietary Inspire therapy is approved by the FDA, EU MDR and PDMA for moderate to severe obstructive sleep apnea, and product updates include the Inspire V system.
Company news commonly covers quarterly and annual results, revenue guidance, cash flow, earnings measures, reimbursement and coding developments, product launch activity, regulatory clearances such as MRI compatibility, executive changes and healthcare conference presentations.
Myomo (NYSE American: MYO) appointed Mary-Katherine McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell after a transition period. Mitchell will remain with the company until December 23, 2026. McClure joins from Inspire Medical Systems, where she had worked since 2018, and brings more than 20 years of experience.
McClure received 275,000 time-based restricted stock units, equity awards that vest subject to continued service, and 225,000 performance-based units at target. The performance award can range from 0% to 150% of target, capped at 337,500 shares. Half depends on financial metrics for 2029; half depends on relative stock-price performance. Myomo's direct provider business now represents approximately 70% of annual revenues.
Inspire Medical Systems (NYSE: INSP) will release its third-quarter 2026 financial results after trading closes on November 2, 2026.
Management will host a conference call at 5:00 p.m. Eastern Time to discuss the results and recent business developments. A webcast will be accessible through the company's Investor Relations website.
Inspire Medical Systems (INSP) announced AMA Editorial Panel approval of new procedure codes covering its Inspire V nerve stimulation system. The Category I Current Procedural Terminology (CPT) codes are scheduled to take effect on January 1, 2028. They address implantation of a single lead and an implantable pulse generator.
Inspire expects the dedicated codes to reduce administrative burdens for hospitals and physicians and support greater patient access. The Centers for Medicare & Medicaid Services (CMS) will determine each code’s value, which sets Medicare payments for the service. Inspire expects proposed valuations in July 2027 and final valuations in November 2027.
Inspire Medical Systems (NYSE: INSP) announced that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m. Eastern Time. The presentation will be available via live webcast with a two-week replay on Inspire’s investor website.
Mobia Medical (Nasdaq: MOBI) appointed Myriam Curet, M.D. to its Board of Directors as an independent director, effective July 30, 2026. The company highlights her combination of clinical, executive and public company board experience to support its stroke recovery business.
Dr. Curet is a Clinical Professor of Surgery at Stanford University School of Medicine, holds a part-time clinical role at the Palo Alto VA Medical Center, and has previously held senior surgical posts at Stanford and the University of New Mexico. She also serves on the boards of Inspire Medical Systems (NYSE: INSP) and Stereotaxis (NYSE American: STXS) and is a Fellow of the American College of Surgeons.
Inspire Medical Systems (NYSE: INSP) reported second quarter 2026 revenue of $200.6 million, down 7.6% year over year, with lower U.S. sales partly offset by international growth. Gross margin improved 150 bps to 85.5%. Operating loss narrowed to $0.5 million, with adjusted operating income of $3.2 million (1.6% margin). Net earnings were $0.3 million, or diluted EPS of $0.01, and adjusted diluted EPS was $0.14.
Operating cash flow rose to $23.2 million, and cash, cash equivalents, and investments were $415.2 million at June 30, 2026. The company raised 2026 revenue guidance to $835–$875 million, with expected adjusted operating margin of 4%–6%. Inspire also launched Project Horizon, a strategic growth plan expected to create about $30 million of annualized investment capacity, supported by $20–$25 million in projected pre-tax restructuring charges through 2026.
Inspire Medical Systems (NYSE: INSP), a medical technology company focused on minimally invasive treatments for obstructive sleep apnea (OSA), appointed seasoned medical device executive Michael H. Carrel to its Board of Directors, effective July 20. Chairman and CEO Tim Herbert said the company looks forward to his guidance as it advances Inspire therapy.
Carrel has served as President, Chief Executive Officer and director of AtriCure (NASDAQ: ATRC) since November 2012. Under his leadership, AtriCure’s revenue grew from $82 million in 2013 to $535 million in 2025, treating more than one million patients. He previously chaired the board of Axonics from 2019 to 2024, through its sale to Boston Scientific. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School. He cited Inspire’s fifth-generation device, product pipeline and growing evidence of long-term cardiovascular benefits as reasons he believes the company is well positioned to expand access for OSA patients.
Inspire Medical Systems (NYSE: INSP) announced that Casey M. Tansey will retire from its Board of Directors on July 30 after more than 18 years of service. Tansey, representing U.S. Venture Partners, led Inspire’s Series A financing in November 2007 and has served on the Board since then. The company expects to appoint a new director to replace him in the near future.
Inspire Medical Systems (NYSE: INSP) corrected its second quarter 2026 earnings release schedule. The company will now report results after market close on Monday, August 3, 2026, followed by a conference call at 5:00 p.m. Eastern Time.
Investors can join via webcast on the Investor Relations website or register for the live call to ask questions. A replay will be posted about two hours after the event and remain available for two weeks.
Inspire Medical Systems (NYSE: INSP) will release its second quarter 2026 financial results after the market close on Monday, August 3, 2026. Management will host a conference call at 5:00 p.m. Eastern Time, with access via webcast and phone registration links.